Dramatic response to modified docetaxel, cisplatin, and fluorouracil chemotherapy after immunotherapy in a patient with refractory metastatic anal cancer

Doublet chemotherapies are the mainstay in the management of metastatic anal cancer. Immunotherapy has been incorporated into guidelines in a refractory setting. Treatment options remain limited with tumor progression beyond immunotherapy. Modified docetaxel, cisplatin, and fluorouracil (mDCF) chemo...

Descripción completa

Detalles Bibliográficos
Autores principales: Shahjehan, Faisal, Kamatham, Saivaishnavi, Ritter, Ashton, Kasi, Pashtoon Murtaza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745381/
https://www.ncbi.nlm.nih.gov/pubmed/31534737
http://dx.doi.org/10.1002/ccr3.2333

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745381/
https://www.ncbi.nlm.nih.gov/pubmed/31534737
http://dx.doi.org/10.1002/ccr3.2333

Ejemplares similares